Search

A summary of the literature regarding the use of adjunctive protein synthesis inhibitors for toxin suppression in the setting of S. aureus infections is presented

Our findings are crucial in demonstrating that the Northern Territory STS clone is not STX resistant

There is a wide spectrum of disease severity in paediatric Staphylococcus aureus bacteraemia

Scabies and impetigo are common in Timor-Leste, with very high prevalence of scabies in the rural district of Ermera

Scabies and impetigo infections are under-recognised and hence under-treated by clinicians

The evidence derived from the review will be used to inform the development of guidelines for the management of skin infections in resource-limited settings

Treatment success for scabies co-infection was lower than for impetigo overall, with a higher success seen in the co-trimoxazole group than benzylpenicillin

We report osteomyelitis incidence in indigenous children of northern Australia is amongst the highest reported in the world

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection.

The social determinants of health such as access to income, education, housing and healthcare, strongly shape the occurrence of acute rheumatic fever and rheumatic heart disease at the household, community and national levels.